8-K: CytoSorbents Appoints Thomas Shannon as VP of Marketing for North America, Eyes DrugSorb-ATR Launch

CytoSorbents Corporation has appointed Thomas Shannon as Vice President of Marketing for North America to lead the marketing strategy for DrugSorb-ATR, pending regulatory approval.

Summary

• CytoSorbents Corporation announced the appointment of Thomas Shannon as Vice President of Marketing for North America on April 14, 2025.
• Shannon will lead the marketing strategy and execution for DrugSorb-ATR in the U.S. and Canada, pending marketing approval.
• DrugSorb-ATR is a U.S. FDA Breakthrough medical device aimed at addressing perioperative bleeding caused by blood thinners in patients undergoing CABG surgery.
• The company expects regulatory decisions from the U.S. FDA and Health Canada regarding DrugSorb-ATR in 2025.
• CytoSorbents submitted a De Novo medical device application to the U.S. FDA in September 2024 and a Medical Device License application to Health Canada in November 2024.
• CytoSorb, the company's lead product, is approved in the European Union and distributed in over 70 countries, with over a quarter million devices used to date.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the appointment of a seasoned executive and the anticipation of regulatory approval for a promising product. However, the dependence on regulatory outcomes and competition temper the overall outlook.

Positives

• The appointment of an experienced marketing executive like Thomas Shannon signals CytoSorbents' readiness for the potential launch of DrugSorb-ATR.
• DrugSorb-ATR has received FDA Breakthrough Device Designations, highlighting its potential to address a critical unmet need in reducing perioperative bleeding.
• The company's existing product, CytoSorb, has a strong track record with approval in the European Union and widespread use in over 70 countries.
• The company's marketing applications for DrugSorb-ATR are currently under substantive review with the FDA and Health Canada.

Negatives

• DrugSorb-ATR is still an investigational device and is not yet approved in the United States and Canada.
• The company's success is contingent on receiving regulatory approval for DrugSorb-ATR from the FDA and Health Canada in 2025.

Risks

• The company's future performance depends on the successful regulatory approval and commercialization of DrugSorb-ATR.
• Delays in regulatory approval or unfavorable decisions could negatively impact the company's prospects.
• The company faces competition in the blood purification market.
• The company's restructuring of its direct sales team and strategy in Germany could impact sales.

Future Outlook

CytoSorbents anticipates regulatory decisions from the U.S. FDA and Health Canada regarding DrugSorb-ATR in 2025 and is preparing for the potential launch of the product in the U.S. and Canada.

Management Comments

• Dr. Phillip Chan, CEO of CytoSorbents, stated that Tom Shannon's leadership and commercial success will be invaluable in driving the successful commercialization of DrugSorb-ATR.
• Tom Shannon commented that he is impressed by the value proposition that DrugSorb-ATR can represent for patients, surgeons, and hospital systems.

Industry Context

This announcement comes as the medical device industry continues to innovate in the area of blood purification and perioperative bleeding management. Companies like Fresenius Medical Care and Getinge (formerly Maquet) are key players in the extracorporeal therapy and cardiac surgery space, making CytoSorbents' DrugSorb-ATR a potential competitor in this market.

Comparison to Industry Standards

• Fresenius Medical Care (NYSE: FMS) is a major player in extracorporeal therapies, and Shannon's experience there gives him insight into competing in that space.
• Getinge (Stockholm GETI-B.ST), formerly Maquet, is a leader in cardiac surgery equipment; Shannon's experience commercializing products there is directly relevant to DrugSorb-ATR's potential market.
• Medtronic (NYSE: MDT) is a broad-based medical technology company; Shannon's experience there in sales, therapy development, and marketing provides a strong foundation for his new role.

Management Changes

Stakeholder Impact

• Shareholders may see a positive impact if DrugSorb-ATR receives regulatory approval and is successfully commercialized.
• Employees may benefit from the company's growth and expansion.
• Patients undergoing CABG surgery could benefit from DrugSorb-ATR's ability to reduce perioperative bleeding.
• Hospitals and surgeons may find DrugSorb-ATR valuable in improving patient outcomes and reducing complications.

Next Steps

• CytoSorbents will continue to work with the FDA and Health Canada to secure regulatory approval for DrugSorb-ATR.
• Thomas Shannon will develop and execute the marketing strategy for DrugSorb-ATR in North America.
• The company will prepare for the potential launch of DrugSorb-ATR in the U.S. and Canada.

Key Dates

Keywords

DrugSorb-ATR, CytoSorbents, Thomas Shannon, Marketing, Blood Purification, CABG, Perioperative Bleeding, FDA, Health Canada, Regulatory Approval